

C Blake Gilks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1384286/publications.pdf>

Version: 2024-02-01

371
papers

35,183
citations

2215

99
h-index

4645

170
g-index

376
all docs

376
docs citations

376
times ranked

29210
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 12-19.	1.4	10
2	The utility of color normalization for AI-based diagnosis of hematoxylin and eosin-stained pathology images. <i>Journal of Pathology</i> , 2022, 256, 15-24.	4.5	19
3	Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). <i>Histopathology</i> , 2022, 80, 762-778.	2.9	46
4	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 ⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
5	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	12.8	46
6	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. <i>Gynecologic Oncology</i> , 2022, 165, 376-384.	1.4	20
7	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. <i>Gynecologic Oncology</i> , 2022, 165, 201-214.	1.4	18
8	The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 395-407.	3.0	3
9	HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva. <i>Modern Pathology</i> , 2022, 35, 1317-1326.	5.5	23
10	Identification of a novel subtype of endometrial cancer with unfavorable outcome using artificial intelligence-based histopathology image analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5594-5594.	1.6	1
11	Primary mucinous ovarian neoplasms rarely show germ cell histogenesis. <i>Histopathology</i> , 2021, 78, 640-642.	2.9	6
12	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. <i>Modern Pathology</i> , 2021, 34, 508-518.	5.5	40
13	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
14	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. <i>Mod Pathol</i> 2020; 33:871-879. <i>Modern Pathology</i> , 2021, 34, 1031-1032.	5.5	6
15	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021, 160, 568-578.	1.4	21
16	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. <i>Human Pathology</i> , 2021, 108, 1-11.	2.0	8
17	Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. <i>Histopathology</i> , 2021, 78, 424-433.	2.9	24
18	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 243-252.	3.0	27

#	ARTICLE	IF	CITATIONS
19	p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 907-913.	2.5	37
20	Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. <i>Journal of Pathology</i> , 2021, 253, 355-365.	4.5	62
21	Online Training and Self-assessment in the Histopathologic Classification of Endocervical Adenocarcinoma and Diagnosis of Pattern of Invasion: Evaluation of Participant Performance. <i>International Journal of Gynecological Pathology</i> , 2021, 40, S14-S23.	1.4	3
22	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 487-494.	1.4	7
23	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	4.1	62
24	Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1038-1046.	3.7	12
25	Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. <i>Histopathology</i> , 2021, 79, 533-543.	2.9	10
26	Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2021, 18, 3464-3474.	4.6	2
27	Ovarian borderline tumours and carcinomas: an update. <i>Diagnostic Histopathology</i> , 2021, 27, 500-505.	0.4	1
28	Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2021, 45, 498-506.	3.7	76
29	Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 391-399.	1.4	7
30	Immunoreactive Acellular Keratin in Sentinel Lymph Nodes From a Patient With Endometrioid Carcinoma of the Endometrium With Squamous Differentiation: A Case Report of a Potential Diagnostic Pitfall. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 355-358.	1.4	0
31	Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. <i>Histopathology</i> , 2020, 76, 521-530.	2.9	6
32	Use of Immunohistochemical Markers (HNF-1 β , Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 344-353.	1.4	14
33	Napsin-A and AMACR are Superior to HNF-1 β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 593-601.	1.2	20
34	The most important discoveries of the past 50 years in gynaecological pathology. <i>Histopathology</i> , 2020, 76, 6-10.	2.9	3
35	The changing landscape of gynaecological pathology: WHO 2020 and beyond. <i>Histopathology</i> , 2020, 76, 2-5.	2.9	2
36	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 552-560.	1.4	49

#	ARTICLE	IF	CITATIONS
37	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 537-545.	1.4	25
38	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	4.5	203
39	Clinicopathological and molecular characterisation of "multiple-classifier" endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	4.5	205
40	p53 immunohistochemistry is an accurate surrogate for <i>TP53</i> mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020, 250, 336-345.	4.5	164
41	Vulval squamous cell carcinoma and its precursors. <i>Histopathology</i> , 2020, 76, 128-138.	2.9	73
42	Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 19-25.	1.4	6
43	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	2.5	29
44	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2020, 44, 495-502.	3.7	16
45	Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 420-427.	1.4	6
46	Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 514-521.	1.4	1
47	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. <i>Journal of Pathology</i> , 2020, 252, 178-188.	4.5	53
48	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin. , 2020, 8, e001128.		14
49	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. <i>Cancer Medicine</i> , 2020, 9, 6507-6514.	2.8	5
50	Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 783-788.	2.5	12
51	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 252-262.	3.0	33
52	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , 2020, 101, 40-52.	2.0	4
53	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	7.0	21
54	Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for <i>TP53</i> mutations in vulvar squamous cell carcinoma. <i>Histopathology</i> , 2020, 77, 92-99.	2.9	42

#	ARTICLE	IF	CITATIONS
55	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
56	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 36-45.	1.4	9
57	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 100-106.	2.5	29
58	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 12-20.	1.4	18
59	Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. <i>Gynecologic Oncology</i> , 2020, 158, 3-11.	1.4	78
60	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. <i>Modern Pathology</i> , 2020, 33, 1595-1605.	5.5	103
61	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. <i>Modern Pathology</i> , 2020, 33, 1649-1659.	5.5	17
62	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020, 15, e0240412.	2.5	1
63	Title is missing!. , 2020, 15, e0240412.		0
64	Title is missing!. , 2020, 15, e0240412.		0
65	Title is missing!. , 2020, 15, e0240412.		0
66	Title is missing!. , 2020, 15, e0240412.		0
67	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 353-362.	1.4	45
68	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. <i>Histopathology</i> , 2019, 75, 813-824.	2.9	19
69	Precision medicine in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 451-453.	1.4	9
70	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	12.8	110
71	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	1.4	74
72	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. <i>Human Pathology</i> , 2019, 92, 39-47.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 353-356.	2.5	15
74	Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma. <i>Histopathology</i> , 2019, 75, 442-445.	2.9	12
75	Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 487-495.	1.4	72
76	Synchronous carcinomas of endometrium and ovary: A pragmatic approach. <i>Gynecologic Oncology Reports</i> , 2019, 27, 72-73.	0.6	11
77	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S40-S63.	1.4	164
78	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 628-638.	3.7	62
79	Minutes of the 2018 Annual Business Meeting of International Society of Gynecological Pathologists (ISGyP). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 108-109.	1.4	0
80	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548.	7.0	101
81	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 119-127.	1.4	10
82	Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 189-195.	1.4	20
83	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S123-S131.	1.4	226
84	Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 558-563.	1.2	28
85	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
86	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018, 42, 561-568.	3.7	214
87	DICER1 hot spot mutations in ovarian gynandroblastoma. <i>Histopathology</i> , 2018, 73, 306-313.	2.9	28
88	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , 2018, 31, 1107-1115.	5.5	49
89	Case report: an identical twin with Sertoli-Leydig cell tumor. <i>Gynecological Endocrinology</i> , 2018, 34, 563-566.	1.7	2
90	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 885-896.	2.8	39

#	ARTICLE	IF	CITATIONS
91	Synchronous tumours of the female reproductive tract. <i>Pathology</i> , 2018, 50, 214-221.	0.6	24
92	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. <i>BMC Cancer</i> , 2018, 18, 254.	2.6	19
93	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018, 18, 347.	2.6	67
94	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	1.9	15
95	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 324-330.	1.4	13
96	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , 2018, 31, 652-659.	5.5	12
97	Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1624-1630.	2.5	8
98	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018, 119, 1401-1409.	6.4	175
99	A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1596-1606.	3.7	115
100	Does MMR status in endometrial cancer influence response to adjuvant therapy?. <i>Gynecologic Oncology</i> , 2018, 151, 76-81.	1.4	25
101	Artefactual punctate <i>MLH1</i> staining can lead to erroneous reporting of isolated <i>PMS2</i> loss. <i>Histopathology</i> , 2018, 73, 703-705.	2.9	11
102	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. <i>British Journal of Cancer</i> , 2018, 119, 480-486.	6.4	86
103	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22.	28.9	261
104	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018, 151, 53-60.	1.4	54
105	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , 2017, 123, 802-813.	4.1	552
106	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017, 23, 4086-4094.	7.0	114
107	Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. <i>Histopathology</i> , 2017, 71, 238-246.	2.9	92
108	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. <i>Histopathology</i> , 2017, 71, 446-452.	2.9	25

#	ARTICLE	IF	CITATIONS
109	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	21.4	220
110	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 555-561.	1.4	40
111	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	27.0	451
112	High-grade serous carcinoma of tubo-ovarian origin: recent developments. <i>Histopathology</i> , 2017, 71, 339-356.	2.9	71
113	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017, 41, 245-252.	3.7	81
114	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 230-239.	1.4	31
115	Ovarian carcinoma histotype in Lynch syndrome. <i>Gynecologic Oncology Reports</i> , 2017, 20, 140-141.	0.6	1
116	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. <i>Histopathology</i> , 2017, 70, 56-69.	2.9	21
117	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 279-293.	3.0	70
118	Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 686-696.	1.1	5
119	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
120	Assessment of CK17 as a Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 273-280.	1.4	27
121	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. <i>Journal of Pathology</i> , 2017, 243, 26-36.	4.5	69
122	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , 2017, 71, 1014-1017.	2.9	6
123	HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 507-516.	1.4	50
124	Frequent NF1B-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 289-293.	1.4	32
125	Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 161-170.	3.7	58
126	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 126-136.	2.8	29

#	ARTICLE	IF	CITATIONS
127	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. <i>Histopathology</i> , 2017, 70, 185-194.	2.9	13
128	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. <i>Nature Reviews Cancer</i> , 2017, 17, 65-74.	28.4	235
129	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 172-179.	1.4	33
130	A comparison of p53 and WT1 immunohistochemical expression patterns in tuboovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , 2017, 71, 736-742.	2.9	27
131	p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 385-393.	1.4	70
132	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 230-237.	1.4	44
133	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , 2016, 69, 727-738.	2.9	52
134	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 209-221.	1.4	28
135	Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours. <i>Histopathology</i> , 2016, 69, 560-569.	2.9	54
136	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 2016, 40, 1155-1164.	3.7	30
137	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. <i>Surgical Pathology Clinics</i> , 2016, 9, 189-199.	1.7	22
138	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , 2016, 48, 758-767.	21.4	287
139	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
140	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	1.4	25
141	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw134.	6.3	52
142	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
143	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	4.5	169
144	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , 2016, 29, 1586-1593.	5.5	87

#	ARTICLE	IF	CITATIONS
145	Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. <i>British Journal of Cancer</i> , 2016, 115, 993-999.	6.4	55
146	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016, 143, 46-53.	1.4	153
147	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , 2016, 45, 119-125.	1.9	20
148	The cell surface mucin podocalyxin regulates collective breast tumor budding. <i>Breast Cancer Research</i> , 2016, 18, 11.	5.0	26
149	Endometrial Carcinomas with <i>POLE</i> Exonuclease Domain Mutations Have a Favorable Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 2865-2873.	7.0	139
150	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 430-441.	1.4	180
151	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 483-490.	2.5	30
152	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 417-426.	6.4	35
153	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	1.4	34
154	Rare cancers: a sea of opportunity. <i>Lancet Oncology</i> , The, 2016, 17, e52-e61.	10.7	76
155	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. <i>Gynecologic Oncology</i> , 2016, 141, 195-198.	1.4	60
156	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 302-314.	5.5	123
157	Histopathological features of endometrial carcinomas associated with <i>POLE</i> mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , 2016, 68, 916-924.	2.9	65
158	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , 2016, 40, 166-180.	3.7	51
159	Endometrial Carcinomas With Clear Cells. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 323-333.	1.4	44
160	FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors. <i>American Journal of Surgical Pathology</i> , 2015, 39, 618-623.	3.7	26
161	Vulvar Acanthosis With Altered Differentiation (VAAD). <i>International Journal of Gynecological Pathology</i> , 2015, 34, 385-389.	1.4	17
162	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 517-527.	1.4	15

#	ARTICLE	IF	CITATIONS
163	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. American Journal of Surgical Pathology, 2015, 39, 1548-1557.	3.7	70
164	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 2015, 6, 37663-37677.	1.8	142
165	Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy. Obstetrics and Gynecology, 2015, 125, 338-345.	2.4	106
166	Expanding the Morphologic Spectrum of Differentiated VIN (dVIN) Through Detailed Mapping of Cases With p53 Loss. American Journal of Surgical Pathology, 2015, 39, 52-60.	3.7	71
167	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. American Journal of Surgical Pathology, 2015, 39, 357-364.	3.7	104
168	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. Journal of Pathology, 2015, 236, 201-209.	4.5	131
169	The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology, 2015, 47, 423-431.	0.6	48
170	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. Journal of the National Cancer Institute, 2015, 108, djv428.	6.3	128
171	Loss of the Notch effector RBPJ promotes tumorigenesis. Journal of Experimental Medicine, 2015, 212, 37-52.	8.5	52
172	Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. FEBS Letters, 2015, 589, 302-309.	2.8	9
173	Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology, 2015, 67, 331-337.	2.9	39
174	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathology, 2015, 28, 1101-1122.	5.5	164
175	Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors. Gynecologic Oncology, 2015, 138, 141-146.	1.4	29
176	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. Gynecologic Oncology, 2015, 139, 268-274.	1.4	50
177	Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. Journal of Clinical Oncology, 2015, 33, 2457-2463.	1.6	203
178	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
179	Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a low-grade serous tubal intra-epithelial carcinoma (STIC) on risk reducing surgery. Gynecologic Oncology Reports, 2015, 12, 72-74.	0.6	8
180	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. Neoplasia, 2015, 17, 650-660.	5.3	59

#	ARTICLE	IF	CITATIONS
181	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 33705-33719.	1.8	28
182	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 255-261.	5.5	110
183	HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1495-1502.	2.5	31
184	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. <i>Genome Research</i> , 2014, 24, 1881-1893.	5.5	322
185	Canadian Association of Pathologistsâ€“Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2014, 142, 629-633.	0.7	12
186	Immunohistochemical characterization of prototypical endometrial clear cell carcinomaâ€”diagnostic utility of <i>HNF1β</i> and oestrogen receptor. <i>Histopathology</i> , 2014, 64, 585-596.	2.9	68
187	Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of <i>FOXL2</i> mutation status. <i>Histopathology</i> , 2014, 64, 626-632.	2.9	21
188	Immunohistochemical Survey of Mismatch Repair Protein Expression in Uterine Sarcomas and Carcinosarcomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 483-491.	1.4	38
189	The Histomorphology of Lynch Syndromeâ€“associated Ovarian Carcinomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1173-1181.	3.7	108
190	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 560-567.	1.4	25
191	Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3967-3973.	1.6	14
192	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. <i>Modern Pathology</i> , 2014, 27, 128-134.	5.5	218
193	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 471.e1-471.e11.	1.3	236
194	Better Therapeutic Trials in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju029-dju029.	6.3	36
195	Mutations in oncogenes: Context matters. <i>Gynecologic Oncology</i> , 2014, 134, 1-2.	1.4	1
196	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , 2014, 27, 1386-1393.	5.5	70
197	Thyroid transcription factor-1 (<i>TTF1</i>) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. <i>Histopathology</i> , 2014, 64, 840-846.	2.9	27
198	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , 2014, 64, 1004-1013.	2.9	104

#	ARTICLE	IF	CITATIONS
199	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. <i>Histopathology</i> , 2014, 65, 149-154.	2.9	69
200	Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. <i>PLoS ONE</i> , 2014, 9, e102370.	2.5	8
201	Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 67-82.	0.4	10
202	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
203	Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: The time has come. <i>Gynecologic Oncology</i> , 2013, 129, 443-444.	1.4	19
204	Patterns of spread of clear cell ovarian cancer: Case report and case series. <i>Gynecologic Oncology Case Reports</i> , 2013, 6, 25-27.	0.9	10
205	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , 2013, 62, 59-70.	2.9	90
206	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. <i>Modern Pathology</i> , 2013, 26, 860-867.	5.5	74
207	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. <i>Cell Cycle</i> , 2013, 12, 1433-1449.	2.6	78
208	Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 529-535.	1.4	34
209	Ovarian Cellular Fibromas Lack FOXL2 Mutations. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1450-1455.	3.7	41
210	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1421-1432.	3.7	115
211	Academic and Nonacademic Laboratories Perform Equally on CIQC Immunohistochemistry Proficiency Testing. <i>American Journal of Clinical Pathology</i> , 2013, 140, 55-60.	0.7	1
212	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1677-1686.	2.5	70
213	Identifying Lynch Syndrome in Patients With Ovarian Carcinoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 378-386.	4.3	52
214	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2013, 121, 14-24.	2.4	134
215	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 442-444.	0.4	0
216	Interobserver Variability in the Interpretation of Tumor Cell Necrosis in Uterine Leiomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 650-658.	3.7	60

#	ARTICLE	IF	CITATIONS
217	Luteinized Thecomas (Thecomatosis) Associated With Sclerosing Peritonitis Exhibit Positive Staining With Sex Cord Markers Steroidogenic Factor-1 (SF-1) and FOXL2. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1458-1459.	3.7	13
218	Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 874-881.	3.7	309
219	Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 514-521.	3.7	79
220	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	5.5	151
221	Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 499-506.	1.4	65
222	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. <i>New England Journal of Medicine</i> , 2012, 366, 234-242.	27.0	401
223	Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation. <i>Journal of Clinical Oncology</i> , 2012, 30, 1656-1662.	1.6	109
224	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 929-934.	7.1	239
225	It Sounded Like a Good Idea at the Time. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 1127-1130.	0.7	14
226	New Insights Into the Pathogenesis of Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2012, 120, 935-940.	2.4	27
227	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 641-653.	3.7	265
228	Utility of a CEA, CD15, Calretinin, and CK5/6 Panel for Distinguishing Between Mesotheliomas and Pulmonary Adenocarcinomas in Clinical Practice. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1503-1508.	3.7	14
229	Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1562-1570.	3.7	184
230	Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. <i>American Journal of Surgery</i> , 2012, 203, 654-659.	1.8	18
231	Use of mutation profiles to refine the classification of endometrial carcinomas. <i>Journal of Pathology</i> , 2012, 228, 20-30.	4.5	261
232	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , 2012, 60, 547-553.	2.9	25
233	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	4.1	71
234	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 239-252.	3.3	50

#	ARTICLE	IF	CITATIONS
235	The role of the fallopian tube in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 296-306.	0.3	77
236	High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum. <i>Surgical Pathology Clinics</i> , 2011, 4, 375-396.	1.7	5
237	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. <i>Nature</i> , 2011, 475, 226-230.	27.8	1,071
238	CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. <i>American Journal of Pathology</i> , 2011, 179, 2100-2107.	3.8	33
239	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , The, 2011, 12, 852-861.	10.7	1,028
240	Frequency of Known Gene Rearrangements in Endometrial Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1364-1372.	3.7	128
241	Biomarker Expression in Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 366-371.	1.4	34
242	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 484-494.	3.7	183
243	Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 36-44.	3.7	129
244	Patterns of p53 immunoreactivity in endometrial carcinomas: "all or nothing"™ staining is of importance. <i>Histopathology</i> , 2011, 59, 786-788.	2.9	76
245	Uterine leiomyosarcomas: Tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. <i>Gynecologic Oncology</i> , 2011, 121, 328-333.	1.4	69
246	Surgical staging of early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 460-461.	1.4	1
247	Subtype-specific mutation of <i>PPP2R1A</i> in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , 2011, 223, 567-573.	4.5	114
248	Loss of BAF250a (<i>ARID1A</i>) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , 2011, 224, 328-333.	4.5	210
249	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	5.5	95
250	Letter to the editor regarding "Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression". <i>Modern Pathology</i> , 2011, 24, 1281-1282.	5.5	6
251	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	7.0	217
252	The Laboratory Score/Reference Method Score Ratio (LSRSR) Is a Novel Tool for Monitoring Laboratory Performance in Immunohistochemistry Proficiency Testing of Hormone Receptors in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2011, 136, 67-73.	0.7	3

#	ARTICLE	IF	CITATIONS
253	Testing Women With Endometrial Cancer to Detect Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, 2247-2252.	1.6	107
254	Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?. <i>Clinical Cancer Research</i> , 2011, 17, 7273-7282.	7.0	23
255	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , 2011, 24, 277-287.	5.5	30
256	Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. <i>Clinical Cancer Research</i> , 2011, 17, 783-791.	7.0	67
257	Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1334-1358.	4.1	33
258	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. <i>PLoS ONE</i> , 2011, 6, e21121.	2.5	71
259	Development of an Evidence-Based Approach to External Quality Assurance for Breast Cancer Hormone Receptor Immunohistochemistry: Comparison of Reference Values. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 874-881.	2.5	9
260	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1132-1138.	3.7	20
261	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. <i>American Journal of Surgical Pathology</i> , 2010, 34, 984-993.	3.7	143
262	HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. <i>Annals of Surgery</i> , 2010, 251, 1107-1116.	4.2	53
263	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 99-107.	1.4	90
264	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 203-211.	1.4	332
265	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 343-350.	1.4	146
266	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. <i>Gynecologic Oncology</i> , 2010, 116, 50-56.	1.4	129
267	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , 2010, 222, 191-198.	4.5	136
268	Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. <i>Pathology</i> , 2010, 42, 637-642.	0.6	6
269	Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	1.3	47
270	Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF- β 2 Pathway Signaling Indicates Response to Primary Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 2852-2860.	7.0	58

#	ARTICLE	IF	CITATIONS
271	Canadian Association of Pathologistsâ€“Association canadienne des pathologistes National Standards Committee/Immunohistochemistry. American Journal of Clinical Pathology, 2010, 133, 354-365.	0.7	74
272	Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum. American Journal of Clinical Pathology, 2010, 134, 835-845.	0.7	152
273	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	27.0	1,460
274	KrÄppel-Like Factor 5 Is Not Required for K-RasG12D Lung Tumorigenesis, but Represses ABCG2 Expression and Is Associated with Better Disease-Specific Survival. American Journal of Pathology, 2010, 177, 1503-1513.	3.8	18
275	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. PLoS ONE, 2009, 4, e6412.	2.5	354
276	MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary. PLoS ONE, 2009, 4, e7314.	2.5	83
277	The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS ONE, 2009, 4, e7988.	2.5	82
278	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. Cancer Research, 2009, 69, 9160-9162.	0.9	58
279	Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. Cancer Research, 2009, 69, 4843-4850.	0.9	40
280	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	5.5	241
281	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	5.5	125
282	A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Modern Pathology, 2009, 22, 1519-1531.	5.5	78
283	Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract. Surgical Pathology Clinics, 2009, 2, 823-834.	1.7	2
284	Ovarian carcinoma pathology and genetics: recent advances. Human Pathology, 2009, 40, 1213-1223.	2.0	211
285	Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. American Journal of Pathology, 2009, 174, 2347-2356.	3.8	83
286	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	27.0	706
287	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	3.7	211
288	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Research and Treatment, 2008, 107, 249-257.	2.5	179

#	ARTICLE	IF	CITATIONS
289	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 417-426.	2.5	91
290	Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 589-598.	2.8	19
291	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 481-489.	2.8	116
292	The fibromatosis signature defines a robust stromal response in breast carcinoma. <i>Laboratory Investigation</i> , 2008, 88, 591-601.	3.7	100
293	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. <i>Modern Pathology</i> , 2008, 21, 1413-1420.	5.5	3
294	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , 2008, 110, 256-264.	1.4	59
295	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, 408-417.	1.4	113
296	The origin of ovarian carcinomas: A developmental view. <i>Gynecologic Oncology</i> , 2008, 110, 452-454.	1.4	67
297	SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. <i>Gynecologic Oncology</i> , 2008, 111, 125-131.	1.4	6
298	Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. <i>Pathology</i> , 2008, 40, 611-616.	0.6	32
299	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008, 39, 1239-1251.	2.0	231
300	Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas. <i>Clinical Cancer Research</i> , 2008, 14, 1423-1430.	7.0	152
301	Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2008, 26, 5697-5704.	1.6	260
302	Endocervical Adenocarcinomas With Ovarian Metastases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1835-1853.	3.7	157
303	Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 955-964.	3.7	84
304	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409.	2.5	37
305	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. <i>PLoS Medicine</i> , 2008, 5, e232.	8.4	675
306	HOXA7 in Epithelial Ovarian Cancer: Interrelationships Between Differentiation and Clinical Features. <i>Reproductive Sciences</i> , 2007, 14, 605-614.	2.5	25

#	ARTICLE	IF	CITATIONS
307	Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. <i>Modern Pathology</i> , 2007, 20, 84-89.	5.5	78
308	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , 2007, 20, 1156-1165.	5.5	58
309	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007, 5, 33.	5.5	52
310	Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment. <i>Annals of Surgical Oncology</i> , 2007, 14, 719-729.	1.5	106
311	Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. <i>American Journal of Surgery</i> , 2006, 191, 581-587.	1.8	54
312	Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. <i>Differentiation</i> , 2006, 74, 1-10.	1.9	44
313	MDM2 protein expression is a negative prognostic marker in breast carcinoma. <i>Modern Pathology</i> , 2006, 19, 69-74.	5.5	62
314	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. <i>Gynecologic Oncology</i> , 2006, 100, 264-270.	1.4	78
315	Immunolocalization of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Type I GnRH Receptor during Follicular Development in the Human Ovary. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4562-4570.	3.6	91
316	Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. <i>Journal of Clinical Oncology</i> , 2006, 24, 5637-5644.	1.6	177
317	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 690-695.	7.1	474
318	Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2. <i>Cancer Research</i> , 2006, 66, 4872-4879.	0.9	139
319	Synchronous and Metachronous Endocervical and Ovarian Neoplasms: A Different Interpretation of HPV Data. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1687-1689.	3.7	5
320	Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems. <i>American Journal of Surgical Pathology</i> , 2005, 29, 295-304.	3.7	101
321	Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2005, 24, 147-152.	1.4	62
322	Aggressive Behavior of Stage I Ovarian Mucinous Tumors Lacking Extensive Infiltrative Invasion: A Report of Four Cases and Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2005, 24, 205-217.	1.4	46
323	Synchronous and Metachronous Endocervical and Ovarian Neoplasms. <i>American Journal of Surgical Pathology</i> , 2005, 29, 281-294.	3.7	128
324	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <i>Oncogene</i> , 2005, 24, 7281-7289.	5.9	63

#	ARTICLE	IF	CITATIONS
325	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. <i>Laboratory Investigation</i> , 2005, 85, 1392-1404.	3.7	107
326	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. <i>Gynecologic Oncology</i> , 2005, 96, 48-55.	1.4	85
327	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. <i>Gynecologic Oncology</i> , 2005, 96, 684-694.	1.4	100
328	Papillary serous carcinoma—A less radio-sensitive subtype of endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 98, 299-303.	1.4	16
329	Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. <i>Cancer</i> , 2005, 103, 1770-1777.	4.1	102
330	Targeted transcriptional repression of Gfi1 by GFI1 and GFI1B in lymphoid cells. <i>Nucleic Acids Research</i> , 2004, 32, 2508-2519.	14.5	74
331	Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6143-6151.	7.0	198
332	Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression. <i>Cancer Research</i> , 2004, 64, 5068-5073.	0.9	136
333	Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells. <i>Cancer Research</i> , 2004, 64, 6874-6882.	0.9	71
334	Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7958-7964.	7.0	17
335	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. <i>Modern Pathology</i> , 2004, 17, 690-695.	5.5	123
336	Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. <i>Gynecologic Oncology</i> , 2004, 93, 315-319.	1.4	25
337	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5367-5374.	7.0	2,393
338	Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 200-205.	1.4	114
339	Early Recurrence of Ovarian Serous Borderline Tumor as High-grade Carcinoma: A Report of Two Cases. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 265-272.	1.4	54
340	Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival. <i>Cancer Research</i> , 2004, 64, 286-291.	0.9	82
341	Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 129-137.	1.4	112
342	Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology. <i>American Journal of Pathology</i> , 2003, 163, 1449-1456.	3.8	133

#	ARTICLE	IF	CITATIONS
343	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans. <i>American Journal of Pathology</i> , 2003, 163, 2383-2395.	3.8	142
344	EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer. <i>Cell</i> , 2003, 115, 523-535.	28.9	389
345	Advanced-Stage Serous Borderline Tumors of the Ovary: A Clinicopathological Study of 49 Cases. <i>International Journal of Gynecological Pathology</i> , 2003, 22, 29-36.	1.4	81
346	Markers of Proliferative Activity Are Predictors of Patient Outcome for Low-Grade Endometrioid Adenocarcinoma But Not Papillary Serous Carcinoma of Endometrium. <i>Modern Pathology</i> , 2002, 15, 365-371.	5.5	40
347	Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry. <i>Modern Pathology</i> , 2002, 15, 1374-1380.	5.5	143
348	Assessment of Interlaboratory Variation in the Immunohistochemical Determination of Estrogen Receptor Status Using a Breast Cancer Tissue Microarray. <i>American Journal of Clinical Pathology</i> , 2002, 117, 723-728.	0.7	150
349	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 1557-1565.	3.8	194
350	Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium. <i>Fertility and Sterility</i> , 2002, 78, 195-196.	1.0	9
351	Amyloidosis of the Uterine Cervix Presenting as Postmenopausal Bleeding. <i>Obstetrics and Gynecology</i> , 2001, 98, 966-968.	2.4	6
352	Early stage uterine papillary serous carcinoma of the endometrium. <i>Cancer</i> , 2001, 91, 752-757.	4.1	70
353	Spontaneous Regression of Stage IV Clear Cell Carcinoma of the Endometrium in a Patient with Essential Thrombocytosis. <i>Gynecologic Oncology</i> , 2001, 82, 395-399.	1.4	6
354	Early stage uterine papillary serous carcinoma of the endometrium. <i>Cancer</i> , 2001, 91, 752-757.	4.1	11
355	Mitotic Arrest of Endometrial Epithelium After Paclitaxel Therapy for Breast Cancer. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 395-397.	1.4	16
356	Uterine Adenomyomas Excluding Atypical Polypoid Adenomyomas and Adenomyomas of Endocervical Type: A Clinicopathologic Study of 30 Cases of an Underemphasized Lesion That May Cause Diagnostic Problems with Brief Consideration of Adenomyomas of Other Female Genital Tract Sites. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 195-205.	1.4	110
357	Acute Cigarette Smoke-Induced Connective Tissue Breakdown Is Mediated by Neutrophils and Prevented by α -1-Antitrypsin. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 244-252.	2.9	145
358	Prognostic Factors in Paget's Disease of the Vulva: A Study of 21 Cases. <i>Obstetrical and Gynecological Survey</i> , 2000, 55, 218-219.	0.4	0
359	Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. <i>J Biol Chem</i> , 1999, 274, 40-48.		38
360	Mineral Dusts Directly Induce Epithelial and Interstitial Fibrogenic Mediators and Matrix Components in the Airway Wall. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 1907-1913.	5.6	65

#	ARTICLE	IF	CITATIONS
361	Papillary Serous Carcinoma of the Uterine Cervix. American Journal of Surgical Pathology, 1998, 22, 113-120.	3.7	82
362	Detection of the EWS/WT1 Gene Fusion by Reverse Transcriptase-Polymerase Chain Reaction in the Diagnosis of Intra-abdominal Desmoplastic Small Round Cell Tumor. American Journal of Surgical Pathology, 1996, 20, 406-412.	3.7	79
363	Small-Cell Carcinoma of the Endometrium. American Journal of Surgical Pathology, 1994, 18, 364-375.	3.7	138
364	Spontaneous Pulmonary Hemorrhage After Thrombolytic Therapy for Acute Myocardial Infarction. Chest, 1994, 106, 1622-1624.	0.8	24
365	Mucinous Tumors of the Appendix Associated With Mucinous Tumors of the Ovary and Pseudomyxoma Peritonei. American Journal of Surgical Pathology, 1991, 15, 415-429.	3.7	325
366	Trichoblastic Fibroma A Clinicopathologic Study of Three Cases. American Journal of Dermatopathology, 1989, 11, 397-402.	0.6	33
367	Biological Effects of Biliary Shock Wave Lithotripsy in Swine. Investigative Radiology, 1989, 24, 366-370.	6.2	7
368	Adenoma Malignum (Minimal Deviation Adenocarcinoma) of the Uterine Cervix. American Journal of Surgical Pathology, 1989, 13, 717-729.	3.7	270
369	Effects of Cigarette Smoke On Tissue Uptake and Retention of Iron Oxide in the Guinea Pig. The American Review of Respiratory Disease, 1988, 137, 1382-1384.	2.9	13
370	A NOVEL LYMPHOCYTE ACTIVATION ANTIGEN PRESENT ON ALLOSPECIFIC PRIMED LYMPHOCYTES AND DEFINED BY THE MONOCLONAL ANTIBODY VG01. Transplantation, 1988, 45, 978-984.	1.0	6
371	Aluminum-Induced Pulmonary Fibrosis: Do Fibers Play a Role?. The American Review of Respiratory Disease, 1987, 136, 176-179.	2.9	44